nodes	percent_of_prediction	percent_of_DWPC	metapath
Letrozole—CYP2A6—Fluorouracil—urinary bladder cancer	0.196	0.527	CbGbCtD
Letrozole—CYP3A4—Thiotepa—urinary bladder cancer	0.12	0.325	CbGbCtD
Letrozole—CYP3A4—Etoposide—urinary bladder cancer	0.0327	0.088	CbGbCtD
Letrozole—CYP3A4—Doxorubicin—urinary bladder cancer	0.0223	0.06	CbGbCtD
Letrozole—CYP19A1—Oxidation by Cytochrome P450—POR—urinary bladder cancer	0.00604	0.0518	CbGpPWpGaD
Letrozole—CYP2A6—Tamoxifen metabolism—UGT2B7—urinary bladder cancer	0.00592	0.0509	CbGpPWpGaD
Letrozole—CYP2A6—Oxidation by Cytochrome P450—POR—urinary bladder cancer	0.00481	0.0413	CbGpPWpGaD
Letrozole—CYP3A4—Codeine and Morphine Metabolism—UGT2B7—urinary bladder cancer	0.0047	0.0404	CbGpPWpGaD
Letrozole—CYP19A1—Cytochrome P450 - arranged by substrate type—CYP4B1—urinary bladder cancer	0.00289	0.0248	CbGpPWpGaD
Letrozole—CYP19A1—Oxidation by Cytochrome P450—CYP4B1—urinary bladder cancer	0.00286	0.0245	CbGpPWpGaD
Letrozole—CYP2A6—Fluoropyrimidine Activity—TYMP—urinary bladder cancer	0.00273	0.0235	CbGpPWpGaD
Letrozole—CYP3A4—Estrogen metabolism—UGT2B7—urinary bladder cancer	0.00246	0.0211	CbGpPWpGaD
Letrozole—CYP19A1—Phase 1 - Functionalization of compounds—CYP4B1—urinary bladder cancer	0.00235	0.0201	CbGpPWpGaD
Letrozole—CYP2A6—Cytochrome P450 - arranged by substrate type—CYP4B1—urinary bladder cancer	0.0023	0.0198	CbGpPWpGaD
Letrozole—CYP2A6—Oxidation by Cytochrome P450—CYP4B1—urinary bladder cancer	0.00227	0.0195	CbGpPWpGaD
Letrozole—CYP19A1—Integrated Breast Cancer Pathway—PHB—urinary bladder cancer	0.00222	0.019	CbGpPWpGaD
Letrozole—CYP3A4—Tamoxifen metabolism—UGT2B7—urinary bladder cancer	0.00217	0.0186	CbGpPWpGaD
Letrozole—CYP2A6—Fluoropyrimidine Activity—RRM2—urinary bladder cancer	0.00213	0.0183	CbGpPWpGaD
Letrozole—CYP19A1—Ovarian Infertility Genes—ESR2—urinary bladder cancer	0.00204	0.0175	CbGpPWpGaD
Letrozole—CYP2A6—Phase 1 - Functionalization of compounds—CYP4B1—urinary bladder cancer	0.00187	0.016	CbGpPWpGaD
Letrozole—CYP2A6—Constitutive Androstane Receptor Pathway—SMC1A—urinary bladder cancer	0.00186	0.016	CbGpPWpGaD
Letrozole—CYP3A4—Oxidation by Cytochrome P450—POR—urinary bladder cancer	0.00176	0.0151	CbGpPWpGaD
Letrozole—CYP19A1—Biological oxidations—GSTZ1—urinary bladder cancer	0.0016	0.0137	CbGpPWpGaD
Letrozole—CYP19A1—Metapathway biotransformation—GSTZ1—urinary bladder cancer	0.00157	0.0135	CbGpPWpGaD
Letrozole—CYP19A1—Ovarian Infertility Genes—NCOR1—urinary bladder cancer	0.00157	0.0135	CbGpPWpGaD
Letrozole—CYP3A4—Aflatoxin B1 metabolism—GSTM1—urinary bladder cancer	0.00155	0.0133	CbGpPWpGaD
Letrozole—CYP19A1—Biological oxidations—GSTO2—urinary bladder cancer	0.00151	0.013	CbGpPWpGaD
Letrozole—CYP19A1—Biological oxidations—NAT1—urinary bladder cancer	0.00151	0.013	CbGpPWpGaD
Letrozole—CYP19A1—Metapathway biotransformation—GSTO2—urinary bladder cancer	0.00149	0.0128	CbGpPWpGaD
Letrozole—CYP19A1—Biological oxidations—UGT2B7—urinary bladder cancer	0.00138	0.0119	CbGpPWpGaD
Letrozole—CYP19A1—Metapathway biotransformation—UGT2B7—urinary bladder cancer	0.00136	0.0117	CbGpPWpGaD
Letrozole—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP4B1—urinary bladder cancer	0.00133	0.0114	CbGpPWpGaD
Letrozole—CYP2A6—Biological oxidations—GSTZ1—urinary bladder cancer	0.00127	0.0109	CbGpPWpGaD
Letrozole—CYP2A6—NRF2 pathway—UGT2B7—urinary bladder cancer	0.00126	0.0108	CbGpPWpGaD
Letrozole—CYP19A1—Biological oxidations—CYP4B1—urinary bladder cancer	0.00125	0.0107	CbGpPWpGaD
Letrozole—CYP19A1—Ovarian Infertility Genes—ATM—urinary bladder cancer	0.00125	0.0107	CbGpPWpGaD
Letrozole—CYP19A1—Ovarian Infertility Genes—CDK4—urinary bladder cancer	0.00124	0.0106	CbGpPWpGaD
Letrozole—CYP2A6—Fluoropyrimidine Activity—TYMS—urinary bladder cancer	0.00124	0.0106	CbGpPWpGaD
Letrozole—CYP19A1—Metapathway biotransformation—CYP4B1—urinary bladder cancer	0.00123	0.0106	CbGpPWpGaD
Letrozole—CYP2A6—Quercetin and Nf-kB/ AP-1 Induced Cell Apoptosis—PTGS2—urinary bladder cancer	0.00123	0.0105	CbGpPWpGaD
Letrozole—CYP2A6—Biological oxidations—GSTO2—urinary bladder cancer	0.0012	0.0103	CbGpPWpGaD
Letrozole—CYP2A6—Biological oxidations—NAT1—urinary bladder cancer	0.0012	0.0103	CbGpPWpGaD
Letrozole—CYP2A6—Fluoropyrimidine Activity—ERCC2—urinary bladder cancer	0.00115	0.00986	CbGpPWpGaD
Letrozole—CYP2A6—Biological oxidations—UGT2B7—urinary bladder cancer	0.0011	0.00946	CbGpPWpGaD
Letrozole—CYP2A6—Fluoropyrimidine Activity—MTHFR—urinary bladder cancer	0.00108	0.00927	CbGpPWpGaD
Letrozole—CYP2A6—Biological oxidations—CYP4B1—urinary bladder cancer	0.000992	0.00852	CbGpPWpGaD
Letrozole—CYP3A4—Estrogen metabolism—NQO1—urinary bladder cancer	0.000949	0.00814	CbGpPWpGaD
Letrozole—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP4B1—urinary bladder cancer	0.000844	0.00725	CbGpPWpGaD
Letrozole—CYP3A4—Oxidation by Cytochrome P450—CYP4B1—urinary bladder cancer	0.000833	0.00715	CbGpPWpGaD
Letrozole—CYP19A1—Biological oxidations—NAT2—urinary bladder cancer	0.000829	0.00712	CbGpPWpGaD
Letrozole—CYP19A1—FSH signaling pathway—SRC—urinary bladder cancer	0.000821	0.00705	CbGpPWpGaD
Letrozole—CYP19A1—Metapathway biotransformation—NAT2—urinary bladder cancer	0.000818	0.00702	CbGpPWpGaD
Letrozole—CYP3A4—Estrogen metabolism—GSTM1—urinary bladder cancer	0.000727	0.00624	CbGpPWpGaD
Letrozole—CYP3A4—Phase 1 - Functionalization of compounds—CYP4B1—urinary bladder cancer	0.000685	0.00588	CbGpPWpGaD
Letrozole—CYP3A4—Constitutive Androstane Receptor Pathway—SMC1A—urinary bladder cancer	0.000682	0.00585	CbGpPWpGaD
Letrozole—CYP19A1—Biological oxidations—HPGDS—urinary bladder cancer	0.000663	0.00569	CbGpPWpGaD
Letrozole—CYP2A6—Biological oxidations—NAT2—urinary bladder cancer	0.00066	0.00567	CbGpPWpGaD
Letrozole—CYP19A1—Integrated Breast Cancer Pathway—TSC1—urinary bladder cancer	0.000656	0.00563	CbGpPWpGaD
Letrozole—CYP19A1—Biological oxidations—GSTT1—urinary bladder cancer	0.000643	0.00552	CbGpPWpGaD
Letrozole—CYP2A6—Biological oxidations—HPGDS—urinary bladder cancer	0.000528	0.00453	CbGpPWpGaD
Letrozole—CYP2A6—Biological oxidations—GSTT1—urinary bladder cancer	0.000512	0.00439	CbGpPWpGaD
Letrozole—CYP2A6—NRF2 pathway—NQO1—urinary bladder cancer	0.000485	0.00416	CbGpPWpGaD
Letrozole—CYP19A1—Metabolism of lipids and lipoproteins—CYP4B1—urinary bladder cancer	0.000478	0.00411	CbGpPWpGaD
Letrozole—CYP3A4—Biological oxidations—GSTZ1—urinary bladder cancer	0.000466	0.004	CbGpPWpGaD
Letrozole—CYP3A4—Metapathway biotransformation—GSTZ1—urinary bladder cancer	0.000459	0.00394	CbGpPWpGaD
Letrozole—CYP19A1—Biological oxidations—GSTP1—urinary bladder cancer	0.000446	0.00383	CbGpPWpGaD
Letrozole—CYP3A4—Biological oxidations—GSTO2—urinary bladder cancer	0.000442	0.00379	CbGpPWpGaD
Letrozole—CYP3A4—Biological oxidations—NAT1—urinary bladder cancer	0.000442	0.00379	CbGpPWpGaD
Letrozole—CYP19A1—Metapathway biotransformation—GSTP1—urinary bladder cancer	0.000439	0.00377	CbGpPWpGaD
Letrozole—CYP3A4—Metapathway biotransformation—GSTO2—urinary bladder cancer	0.000435	0.00374	CbGpPWpGaD
Letrozole—Decreased appetite—Etoposide—urinary bladder cancer	0.00041	0.0008	CcSEcCtD
Letrozole—CYP2A6—Fluoropyrimidine Activity—TP53—urinary bladder cancer	0.00041	0.00352	CbGpPWpGaD
Letrozole—CYP19A1—Biological oxidations—GSTM1—urinary bladder cancer	0.000409	0.00352	CbGpPWpGaD
Letrozole—Gastrointestinal disorder—Etoposide—urinary bladder cancer	0.000407	0.000795	CcSEcCtD
Letrozole—Body temperature increased—Cisplatin—urinary bladder cancer	0.000407	0.000795	CcSEcCtD
Letrozole—Fatigue—Etoposide—urinary bladder cancer	0.000407	0.000794	CcSEcCtD
Letrozole—CYP2A6—NRF2 pathway—GSTP1—urinary bladder cancer	0.000404	0.00347	CbGpPWpGaD
Letrozole—Stomatitis—Epirubicin—urinary bladder cancer	0.000404	0.000789	CcSEcCtD
Letrozole—CYP3A4—Biological oxidations—UGT2B7—urinary bladder cancer	0.000404	0.00347	CbGpPWpGaD
Letrozole—CYP19A1—Metapathway biotransformation—GSTM1—urinary bladder cancer	0.000404	0.00347	CbGpPWpGaD
Letrozole—Constipation—Etoposide—urinary bladder cancer	0.000404	0.000787	CcSEcCtD
Letrozole—Pain—Etoposide—urinary bladder cancer	0.000404	0.000787	CcSEcCtD
Letrozole—Urinary tract infection—Epirubicin—urinary bladder cancer	0.000403	0.000787	CcSEcCtD
Letrozole—Haemoglobin—Methotrexate—urinary bladder cancer	0.0004	0.00078	CcSEcCtD
Letrozole—CYP3A4—Metapathway biotransformation—UGT2B7—urinary bladder cancer	0.000398	0.00342	CbGpPWpGaD
Letrozole—Hepatitis—Methotrexate—urinary bladder cancer	0.000398	0.000776	CcSEcCtD
Letrozole—Haemorrhage—Methotrexate—urinary bladder cancer	0.000398	0.000776	CcSEcCtD
Letrozole—Sweating—Epirubicin—urinary bladder cancer	0.000398	0.000776	CcSEcCtD
Letrozole—Pollakiuria—Doxorubicin—urinary bladder cancer	0.000398	0.000776	CcSEcCtD
Letrozole—Asthenia—Gemcitabine—urinary bladder cancer	0.000396	0.000774	CcSEcCtD
Letrozole—Urinary tract disorder—Methotrexate—urinary bladder cancer	0.000393	0.000767	CcSEcCtD
Letrozole—Hepatobiliary disease—Epirubicin—urinary bladder cancer	0.000392	0.000765	CcSEcCtD
Letrozole—Weight increased—Doxorubicin—urinary bladder cancer	0.000392	0.000764	CcSEcCtD
Letrozole—Pruritus—Gemcitabine—urinary bladder cancer	0.000391	0.000763	CcSEcCtD
Letrozole—Nausea—Thiotepa—urinary bladder cancer	0.00039	0.000761	CcSEcCtD
Letrozole—Urethral disorder—Methotrexate—urinary bladder cancer	0.00039	0.000761	CcSEcCtD
Letrozole—Weight decreased—Doxorubicin—urinary bladder cancer	0.000389	0.00076	CcSEcCtD
Letrozole—Feeling abnormal—Etoposide—urinary bladder cancer	0.000389	0.000759	CcSEcCtD
Letrozole—Gastrointestinal pain—Etoposide—urinary bladder cancer	0.000386	0.000753	CcSEcCtD
Letrozole—Pruritus—Fluorouracil—urinary bladder cancer	0.000384	0.00075	CcSEcCtD
Letrozole—Infestation NOS—Doxorubicin—urinary bladder cancer	0.000384	0.000749	CcSEcCtD
Letrozole—Infestation—Doxorubicin—urinary bladder cancer	0.000384	0.000749	CcSEcCtD
Letrozole—Diarrhoea—Gemcitabine—urinary bladder cancer	0.000378	0.000738	CcSEcCtD
Letrozole—Erythema multiforme—Methotrexate—urinary bladder cancer	0.000376	0.000734	CcSEcCtD
Letrozole—Urticaria—Etoposide—urinary bladder cancer	0.000375	0.000731	CcSEcCtD
Letrozole—Haemoglobin—Epirubicin—urinary bladder cancer	0.000374	0.00073	CcSEcCtD
Letrozole—Stomatitis—Doxorubicin—urinary bladder cancer	0.000374	0.00073	CcSEcCtD
Letrozole—Abdominal pain—Etoposide—urinary bladder cancer	0.000373	0.000728	CcSEcCtD
Letrozole—Body temperature increased—Etoposide—urinary bladder cancer	0.000373	0.000728	CcSEcCtD
Letrozole—Urinary tract infection—Doxorubicin—urinary bladder cancer	0.000373	0.000728	CcSEcCtD
Letrozole—Haemorrhage—Epirubicin—urinary bladder cancer	0.000372	0.000726	CcSEcCtD
Letrozole—Hepatitis—Epirubicin—urinary bladder cancer	0.000372	0.000726	CcSEcCtD
Letrozole—Eye disorder—Methotrexate—urinary bladder cancer	0.000372	0.000725	CcSEcCtD
Letrozole—Diarrhoea—Fluorouracil—urinary bladder cancer	0.000372	0.000725	CcSEcCtD
Letrozole—CYP2A6—NRF2 pathway—GSTM1—urinary bladder cancer	0.000372	0.00319	CbGpPWpGaD
Letrozole—Hypoaesthesia—Epirubicin—urinary bladder cancer	0.00037	0.000723	CcSEcCtD
Letrozole—Asthenia—Cisplatin—urinary bladder cancer	0.00037	0.000721	CcSEcCtD
Letrozole—Cardiac disorder—Methotrexate—urinary bladder cancer	0.000369	0.00072	CcSEcCtD
Letrozole—Sweating—Doxorubicin—urinary bladder cancer	0.000368	0.000718	CcSEcCtD
Letrozole—Urinary tract disorder—Epirubicin—urinary bladder cancer	0.000368	0.000717	CcSEcCtD
Letrozole—Oedema peripheral—Epirubicin—urinary bladder cancer	0.000367	0.000716	CcSEcCtD
Letrozole—Connective tissue disorder—Epirubicin—urinary bladder cancer	0.000366	0.000714	CcSEcCtD
Letrozole—Urethral disorder—Epirubicin—urinary bladder cancer	0.000365	0.000712	CcSEcCtD
Letrozole—CYP3A4—Biological oxidations—CYP4B1—urinary bladder cancer	0.000364	0.00312	CbGpPWpGaD
Letrozole—Hepatobiliary disease—Doxorubicin—urinary bladder cancer	0.000363	0.000708	CcSEcCtD
Letrozole—Angiopathy—Methotrexate—urinary bladder cancer	0.000361	0.000704	CcSEcCtD
Letrozole—CYP19A1—Integrated Breast Cancer Pathway—ATM—urinary bladder cancer	0.00036	0.00309	CbGpPWpGaD
Letrozole—Dizziness—Fluorouracil—urinary bladder cancer	0.000359	0.000701	CcSEcCtD
Letrozole—CYP3A4—Metapathway biotransformation—CYP4B1—urinary bladder cancer	0.000359	0.00308	CbGpPWpGaD
Letrozole—Mediastinal disorder—Methotrexate—urinary bladder cancer	0.000359	0.0007	CcSEcCtD
Letrozole—CYP19A1—Integrated Breast Cancer Pathway—CDK4—urinary bladder cancer	0.000358	0.00308	CbGpPWpGaD
Letrozole—CYP19A1—Integrated Breast Cancer Pathway—ESR1—urinary bladder cancer	0.000357	0.00306	CbGpPWpGaD
Letrozole—CYP2A6—Biological oxidations—GSTP1—urinary bladder cancer	0.000355	0.00305	CbGpPWpGaD
Letrozole—Diarrhoea—Cisplatin—urinary bladder cancer	0.000352	0.000688	CcSEcCtD
Letrozole—Erythema multiforme—Epirubicin—urinary bladder cancer	0.000352	0.000687	CcSEcCtD
Letrozole—Alopecia—Methotrexate—urinary bladder cancer	0.000352	0.000686	CcSEcCtD
Letrozole—Vomiting—Gemcitabine—urinary bladder cancer	0.000351	0.000686	CcSEcCtD
Letrozole—Mental disorder—Methotrexate—urinary bladder cancer	0.000349	0.00068	CcSEcCtD
Letrozole—Rash—Gemcitabine—urinary bladder cancer	0.000348	0.00068	CcSEcCtD
Letrozole—Dermatitis—Gemcitabine—urinary bladder cancer	0.000348	0.000679	CcSEcCtD
Letrozole—Eye disorder—Epirubicin—urinary bladder cancer	0.000348	0.000679	CcSEcCtD
Letrozole—Malnutrition—Methotrexate—urinary bladder cancer	0.000346	0.000676	CcSEcCtD
Letrozole—Haemoglobin—Doxorubicin—urinary bladder cancer	0.000346	0.000676	CcSEcCtD
Letrozole—Headache—Gemcitabine—urinary bladder cancer	0.000346	0.000676	CcSEcCtD
Letrozole—Cardiac disorder—Epirubicin—urinary bladder cancer	0.000346	0.000674	CcSEcCtD
Letrozole—Flushing—Epirubicin—urinary bladder cancer	0.000346	0.000674	CcSEcCtD
Letrozole—Vomiting—Fluorouracil—urinary bladder cancer	0.000345	0.000674	CcSEcCtD
Letrozole—Haemorrhage—Doxorubicin—urinary bladder cancer	0.000344	0.000672	CcSEcCtD
Letrozole—Hepatitis—Doxorubicin—urinary bladder cancer	0.000344	0.000672	CcSEcCtD
Letrozole—Hypoaesthesia—Doxorubicin—urinary bladder cancer	0.000343	0.000669	CcSEcCtD
Letrozole—Rash—Fluorouracil—urinary bladder cancer	0.000343	0.000668	CcSEcCtD
Letrozole—Dermatitis—Fluorouracil—urinary bladder cancer	0.000342	0.000668	CcSEcCtD
Letrozole—Headache—Fluorouracil—urinary bladder cancer	0.00034	0.000664	CcSEcCtD
Letrozole—Urinary tract disorder—Doxorubicin—urinary bladder cancer	0.00034	0.000664	CcSEcCtD
Letrozole—Oedema peripheral—Doxorubicin—urinary bladder cancer	0.000339	0.000662	CcSEcCtD
Letrozole—Dysgeusia—Methotrexate—urinary bladder cancer	0.000339	0.000662	CcSEcCtD
Letrozole—Asthenia—Etoposide—urinary bladder cancer	0.000339	0.000661	CcSEcCtD
Letrozole—Connective tissue disorder—Doxorubicin—urinary bladder cancer	0.000339	0.000661	CcSEcCtD
Letrozole—Angiopathy—Epirubicin—urinary bladder cancer	0.000338	0.000659	CcSEcCtD
Letrozole—Urethral disorder—Doxorubicin—urinary bladder cancer	0.000338	0.000659	CcSEcCtD
Letrozole—Mediastinal disorder—Epirubicin—urinary bladder cancer	0.000336	0.000655	CcSEcCtD
Letrozole—Back pain—Methotrexate—urinary bladder cancer	0.000335	0.000654	CcSEcCtD
Letrozole—Pruritus—Etoposide—urinary bladder cancer	0.000334	0.000651	CcSEcCtD
Letrozole—Alopecia—Epirubicin—urinary bladder cancer	0.000329	0.000642	CcSEcCtD
Letrozole—Nausea—Gemcitabine—urinary bladder cancer	0.000328	0.000641	CcSEcCtD
Letrozole—Vomiting—Cisplatin—urinary bladder cancer	0.000327	0.000639	CcSEcCtD
Letrozole—Vision blurred—Methotrexate—urinary bladder cancer	0.000326	0.000637	CcSEcCtD
Letrozole—Mental disorder—Epirubicin—urinary bladder cancer	0.000326	0.000636	CcSEcCtD
Letrozole—CYP2A6—Biological oxidations—GSTM1—urinary bladder cancer	0.000326	0.0028	CbGpPWpGaD
Letrozole—Erythema multiforme—Doxorubicin—urinary bladder cancer	0.000326	0.000636	CcSEcCtD
Letrozole—Rash—Cisplatin—urinary bladder cancer	0.000325	0.000634	CcSEcCtD
Letrozole—Dermatitis—Cisplatin—urinary bladder cancer	0.000324	0.000633	CcSEcCtD
Letrozole—Malnutrition—Epirubicin—urinary bladder cancer	0.000324	0.000632	CcSEcCtD
Letrozole—Diarrhoea—Etoposide—urinary bladder cancer	0.000323	0.00063	CcSEcCtD
Letrozole—Nausea—Fluorouracil—urinary bladder cancer	0.000323	0.00063	CcSEcCtD
Letrozole—Eye disorder—Doxorubicin—urinary bladder cancer	0.000322	0.000628	CcSEcCtD
Letrozole—Ill-defined disorder—Methotrexate—urinary bladder cancer	0.000321	0.000627	CcSEcCtD
Letrozole—Cardiac disorder—Doxorubicin—urinary bladder cancer	0.00032	0.000624	CcSEcCtD
Letrozole—Flushing—Doxorubicin—urinary bladder cancer	0.00032	0.000624	CcSEcCtD
Letrozole—Tension—Epirubicin—urinary bladder cancer	0.000318	0.000621	CcSEcCtD
Letrozole—Dysgeusia—Epirubicin—urinary bladder cancer	0.000317	0.000619	CcSEcCtD
Letrozole—Nervousness—Epirubicin—urinary bladder cancer	0.000315	0.000614	CcSEcCtD
Letrozole—Back pain—Epirubicin—urinary bladder cancer	0.000313	0.000612	CcSEcCtD
Letrozole—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—urinary bladder cancer	0.000313	0.00269	CbGpPWpGaD
Letrozole—Angiopathy—Doxorubicin—urinary bladder cancer	0.000313	0.00061	CcSEcCtD
Letrozole—Malaise—Methotrexate—urinary bladder cancer	0.000312	0.000609	CcSEcCtD
Letrozole—Dizziness—Etoposide—urinary bladder cancer	0.000312	0.000609	CcSEcCtD
Letrozole—CYP19A1—Integrated Breast Cancer Pathway—RB1—urinary bladder cancer	0.000312	0.00268	CbGpPWpGaD
Letrozole—Vertigo—Methotrexate—urinary bladder cancer	0.000311	0.000607	CcSEcCtD
Letrozole—CYP19A1—Integrated Breast Cancer Pathway—CDH1—urinary bladder cancer	0.000311	0.00267	CbGpPWpGaD
Letrozole—Mediastinal disorder—Doxorubicin—urinary bladder cancer	0.00031	0.000606	CcSEcCtD
Letrozole—Leukopenia—Methotrexate—urinary bladder cancer	0.00031	0.000605	CcSEcCtD
Letrozole—Nausea—Cisplatin—urinary bladder cancer	0.000306	0.000597	CcSEcCtD
Letrozole—Vision blurred—Epirubicin—urinary bladder cancer	0.000305	0.000596	CcSEcCtD
Letrozole—Alopecia—Doxorubicin—urinary bladder cancer	0.000304	0.000594	CcSEcCtD
Letrozole—Cough—Methotrexate—urinary bladder cancer	0.000302	0.00059	CcSEcCtD
Letrozole—Mental disorder—Doxorubicin—urinary bladder cancer	0.000302	0.000589	CcSEcCtD
Letrozole—Ill-defined disorder—Epirubicin—urinary bladder cancer	0.000301	0.000587	CcSEcCtD
Letrozole—Vomiting—Etoposide—urinary bladder cancer	0.0003	0.000585	CcSEcCtD
Letrozole—Malnutrition—Doxorubicin—urinary bladder cancer	0.0003	0.000585	CcSEcCtD
Letrozole—Rash—Etoposide—urinary bladder cancer	0.000298	0.000581	CcSEcCtD
Letrozole—Dermatitis—Etoposide—urinary bladder cancer	0.000297	0.00058	CcSEcCtD
Letrozole—Headache—Etoposide—urinary bladder cancer	0.000296	0.000577	CcSEcCtD
Letrozole—Arthralgia—Methotrexate—urinary bladder cancer	0.000295	0.000575	CcSEcCtD
Letrozole—Myalgia—Methotrexate—urinary bladder cancer	0.000295	0.000575	CcSEcCtD
Letrozole—Chest pain—Methotrexate—urinary bladder cancer	0.000295	0.000575	CcSEcCtD
Letrozole—Tension—Doxorubicin—urinary bladder cancer	0.000294	0.000574	CcSEcCtD
Letrozole—Dysgeusia—Doxorubicin—urinary bladder cancer	0.000294	0.000573	CcSEcCtD
Letrozole—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—urinary bladder cancer	0.000293	0.000571	CcSEcCtD
Letrozole—Malaise—Epirubicin—urinary bladder cancer	0.000292	0.00057	CcSEcCtD
Letrozole—Discomfort—Methotrexate—urinary bladder cancer	0.000291	0.000568	CcSEcCtD
Letrozole—Nervousness—Doxorubicin—urinary bladder cancer	0.000291	0.000568	CcSEcCtD
Letrozole—Vertigo—Epirubicin—urinary bladder cancer	0.000291	0.000568	CcSEcCtD
Letrozole—Leukopenia—Epirubicin—urinary bladder cancer	0.00029	0.000566	CcSEcCtD
Letrozole—Back pain—Doxorubicin—urinary bladder cancer	0.00029	0.000566	CcSEcCtD
Letrozole—Palpitations—Epirubicin—urinary bladder cancer	0.000286	0.000559	CcSEcCtD
Letrozole—Cough—Epirubicin—urinary bladder cancer	0.000283	0.000552	CcSEcCtD
Letrozole—Anaphylactic shock—Methotrexate—urinary bladder cancer	0.000283	0.000552	CcSEcCtD
Letrozole—Vision blurred—Doxorubicin—urinary bladder cancer	0.000283	0.000551	CcSEcCtD
Letrozole—Infection—Methotrexate—urinary bladder cancer	0.000281	0.000548	CcSEcCtD
Letrozole—Nausea—Etoposide—urinary bladder cancer	0.00028	0.000547	CcSEcCtD
Letrozole—Hypertension—Epirubicin—urinary bladder cancer	0.00028	0.000546	CcSEcCtD
Letrozole—Ill-defined disorder—Doxorubicin—urinary bladder cancer	0.000278	0.000543	CcSEcCtD
Letrozole—Nervous system disorder—Methotrexate—urinary bladder cancer	0.000277	0.000541	CcSEcCtD
Letrozole—Chest pain—Epirubicin—urinary bladder cancer	0.000276	0.000538	CcSEcCtD
Letrozole—Myalgia—Epirubicin—urinary bladder cancer	0.000276	0.000538	CcSEcCtD
Letrozole—Arthralgia—Epirubicin—urinary bladder cancer	0.000276	0.000538	CcSEcCtD
Letrozole—Anxiety—Epirubicin—urinary bladder cancer	0.000275	0.000537	CcSEcCtD
Letrozole—Skin disorder—Methotrexate—urinary bladder cancer	0.000275	0.000536	CcSEcCtD
Letrozole—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—urinary bladder cancer	0.000274	0.000535	CcSEcCtD
Letrozole—Hyperhidrosis—Methotrexate—urinary bladder cancer	0.000273	0.000533	CcSEcCtD
Letrozole—CYP19A1—Metabolism—GSTZ1—urinary bladder cancer	0.000273	0.00234	CbGpPWpGaD
Letrozole—Discomfort—Epirubicin—urinary bladder cancer	0.000273	0.000532	CcSEcCtD
Letrozole—Malaise—Doxorubicin—urinary bladder cancer	0.00027	0.000528	CcSEcCtD
Letrozole—Dry mouth—Epirubicin—urinary bladder cancer	0.00027	0.000527	CcSEcCtD
Letrozole—Vertigo—Doxorubicin—urinary bladder cancer	0.000269	0.000526	CcSEcCtD
Letrozole—Anorexia—Methotrexate—urinary bladder cancer	0.000269	0.000526	CcSEcCtD
Letrozole—Leukopenia—Doxorubicin—urinary bladder cancer	0.000268	0.000524	CcSEcCtD
Letrozole—Palpitations—Doxorubicin—urinary bladder cancer	0.000265	0.000517	CcSEcCtD
Letrozole—Anaphylactic shock—Epirubicin—urinary bladder cancer	0.000264	0.000516	CcSEcCtD
Letrozole—Oedema—Epirubicin—urinary bladder cancer	0.000264	0.000516	CcSEcCtD
Letrozole—Infection—Epirubicin—urinary bladder cancer	0.000263	0.000513	CcSEcCtD
Letrozole—Cough—Doxorubicin—urinary bladder cancer	0.000262	0.000511	CcSEcCtD
Letrozole—Nervous system disorder—Epirubicin—urinary bladder cancer	0.000259	0.000506	CcSEcCtD
Letrozole—Hypertension—Doxorubicin—urinary bladder cancer	0.000259	0.000505	CcSEcCtD
Letrozole—CYP19A1—Metabolism—GSTO2—urinary bladder cancer	0.000259	0.00222	CbGpPWpGaD
Letrozole—CYP19A1—Metabolism—NAT1—urinary bladder cancer	0.000259	0.00222	CbGpPWpGaD
Letrozole—Tachycardia—Epirubicin—urinary bladder cancer	0.000258	0.000504	CcSEcCtD
Letrozole—Musculoskeletal discomfort—Methotrexate—urinary bladder cancer	0.000257	0.000502	CcSEcCtD
Letrozole—Skin disorder—Epirubicin—urinary bladder cancer	0.000257	0.000501	CcSEcCtD
Letrozole—Hyperhidrosis—Epirubicin—urinary bladder cancer	0.000256	0.000499	CcSEcCtD
Letrozole—Insomnia—Methotrexate—urinary bladder cancer	0.000256	0.000499	CcSEcCtD
Letrozole—Myalgia—Doxorubicin—urinary bladder cancer	0.000255	0.000498	CcSEcCtD
Letrozole—Arthralgia—Doxorubicin—urinary bladder cancer	0.000255	0.000498	CcSEcCtD
Letrozole—Chest pain—Doxorubicin—urinary bladder cancer	0.000255	0.000498	CcSEcCtD
Letrozole—CYP19A1—Metabolism of lipids and lipoproteins—HPGDS—urinary bladder cancer	0.000254	0.00219	CbGpPWpGaD
Letrozole—Anxiety—Doxorubicin—urinary bladder cancer	0.000254	0.000496	CcSEcCtD
Letrozole—Paraesthesia—Methotrexate—urinary bladder cancer	0.000254	0.000495	CcSEcCtD
Letrozole—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—urinary bladder cancer	0.000254	0.000495	CcSEcCtD
Letrozole—Discomfort—Doxorubicin—urinary bladder cancer	0.000252	0.000492	CcSEcCtD
Letrozole—Anorexia—Epirubicin—urinary bladder cancer	0.000252	0.000492	CcSEcCtD
Letrozole—Dyspnoea—Methotrexate—urinary bladder cancer	0.000252	0.000492	CcSEcCtD
Letrozole—Somnolence—Methotrexate—urinary bladder cancer	0.000251	0.00049	CcSEcCtD
Letrozole—Dry mouth—Doxorubicin—urinary bladder cancer	0.00025	0.000487	CcSEcCtD
Letrozole—Dyspepsia—Methotrexate—urinary bladder cancer	0.000249	0.000485	CcSEcCtD
Letrozole—Decreased appetite—Methotrexate—urinary bladder cancer	0.000246	0.000479	CcSEcCtD
Letrozole—Anaphylactic shock—Doxorubicin—urinary bladder cancer	0.000245	0.000478	CcSEcCtD
Letrozole—Oedema—Doxorubicin—urinary bladder cancer	0.000245	0.000478	CcSEcCtD
Letrozole—Gastrointestinal disorder—Methotrexate—urinary bladder cancer	0.000244	0.000476	CcSEcCtD
Letrozole—Fatigue—Methotrexate—urinary bladder cancer	0.000244	0.000476	CcSEcCtD
Letrozole—Infection—Doxorubicin—urinary bladder cancer	0.000243	0.000474	CcSEcCtD
Letrozole—CYP3A4—Biological oxidations—NAT2—urinary bladder cancer	0.000242	0.00208	CbGpPWpGaD
Letrozole—Pain—Methotrexate—urinary bladder cancer	0.000242	0.000472	CcSEcCtD
Letrozole—Musculoskeletal discomfort—Epirubicin—urinary bladder cancer	0.000241	0.00047	CcSEcCtD
Letrozole—Nervous system disorder—Doxorubicin—urinary bladder cancer	0.00024	0.000468	CcSEcCtD
Letrozole—Insomnia—Epirubicin—urinary bladder cancer	0.000239	0.000467	CcSEcCtD
Letrozole—Tachycardia—Doxorubicin—urinary bladder cancer	0.000239	0.000466	CcSEcCtD
Letrozole—CYP3A4—Metapathway biotransformation—NAT2—urinary bladder cancer	0.000239	0.00205	CbGpPWpGaD
Letrozole—Skin disorder—Doxorubicin—urinary bladder cancer	0.000238	0.000464	CcSEcCtD
Letrozole—Paraesthesia—Epirubicin—urinary bladder cancer	0.000238	0.000463	CcSEcCtD
Letrozole—CYP19A1—Metabolism—UGT2B7—urinary bladder cancer	0.000237	0.00203	CbGpPWpGaD
Letrozole—Hyperhidrosis—Doxorubicin—urinary bladder cancer	0.000237	0.000462	CcSEcCtD
Letrozole—Dyspnoea—Epirubicin—urinary bladder cancer	0.000236	0.00046	CcSEcCtD
Letrozole—Somnolence—Epirubicin—urinary bladder cancer	0.000235	0.000459	CcSEcCtD
Letrozole—Anorexia—Doxorubicin—urinary bladder cancer	0.000233	0.000455	CcSEcCtD
Letrozole—Feeling abnormal—Methotrexate—urinary bladder cancer	0.000233	0.000454	CcSEcCtD
Letrozole—Dyspepsia—Epirubicin—urinary bladder cancer	0.000233	0.000454	CcSEcCtD
Letrozole—CYP19A1—Integrated Breast Cancer Pathway—CCND1—urinary bladder cancer	0.000231	0.00199	CbGpPWpGaD
Letrozole—Gastrointestinal pain—Methotrexate—urinary bladder cancer	0.000231	0.000451	CcSEcCtD
Letrozole—Decreased appetite—Epirubicin—urinary bladder cancer	0.00023	0.000449	CcSEcCtD
Letrozole—Gastrointestinal disorder—Epirubicin—urinary bladder cancer	0.000228	0.000446	CcSEcCtD
Letrozole—Fatigue—Epirubicin—urinary bladder cancer	0.000228	0.000445	CcSEcCtD
Letrozole—Pain—Epirubicin—urinary bladder cancer	0.000226	0.000441	CcSEcCtD
Letrozole—Constipation—Epirubicin—urinary bladder cancer	0.000226	0.000441	CcSEcCtD
Letrozole—Urticaria—Methotrexate—urinary bladder cancer	0.000225	0.000438	CcSEcCtD
Letrozole—Body temperature increased—Methotrexate—urinary bladder cancer	0.000223	0.000436	CcSEcCtD
Letrozole—Abdominal pain—Methotrexate—urinary bladder cancer	0.000223	0.000436	CcSEcCtD
Letrozole—CYP19A1—Integrated Breast Cancer Pathway—PTEN—urinary bladder cancer	0.000223	0.00192	CbGpPWpGaD
Letrozole—Musculoskeletal discomfort—Doxorubicin—urinary bladder cancer	0.000223	0.000435	CcSEcCtD
Letrozole—Insomnia—Doxorubicin—urinary bladder cancer	0.000221	0.000432	CcSEcCtD
Letrozole—Paraesthesia—Doxorubicin—urinary bladder cancer	0.00022	0.000429	CcSEcCtD
Letrozole—Dyspnoea—Doxorubicin—urinary bladder cancer	0.000218	0.000426	CcSEcCtD
Letrozole—Feeling abnormal—Epirubicin—urinary bladder cancer	0.000218	0.000425	CcSEcCtD
Letrozole—Somnolence—Doxorubicin—urinary bladder cancer	0.000218	0.000425	CcSEcCtD
Letrozole—CYP2A6—Metabolism—GSTZ1—urinary bladder cancer	0.000217	0.00187	CbGpPWpGaD
Letrozole—Gastrointestinal pain—Epirubicin—urinary bladder cancer	0.000216	0.000422	CcSEcCtD
Letrozole—Dyspepsia—Doxorubicin—urinary bladder cancer	0.000215	0.00042	CcSEcCtD
Letrozole—CYP19A1—Metabolism—CYP4B1—urinary bladder cancer	0.000213	0.00183	CbGpPWpGaD
Letrozole—CYP19A1—Integrated Breast Cancer Pathway—EP300—urinary bladder cancer	0.000213	0.00183	CbGpPWpGaD
Letrozole—Decreased appetite—Doxorubicin—urinary bladder cancer	0.000213	0.000415	CcSEcCtD
Letrozole—Gastrointestinal disorder—Doxorubicin—urinary bladder cancer	0.000211	0.000412	CcSEcCtD
Letrozole—Fatigue—Doxorubicin—urinary bladder cancer	0.000211	0.000412	CcSEcCtD
Letrozole—Urticaria—Epirubicin—urinary bladder cancer	0.00021	0.00041	CcSEcCtD
Letrozole—Pain—Doxorubicin—urinary bladder cancer	0.000209	0.000408	CcSEcCtD
Letrozole—Constipation—Doxorubicin—urinary bladder cancer	0.000209	0.000408	CcSEcCtD
Letrozole—Abdominal pain—Epirubicin—urinary bladder cancer	0.000209	0.000408	CcSEcCtD
Letrozole—Body temperature increased—Epirubicin—urinary bladder cancer	0.000209	0.000408	CcSEcCtD
Letrozole—CYP2A6—Metabolism—GSTO2—urinary bladder cancer	0.000206	0.00177	CbGpPWpGaD
Letrozole—CYP2A6—Metabolism—NAT1—urinary bladder cancer	0.000206	0.00177	CbGpPWpGaD
Letrozole—Asthenia—Methotrexate—urinary bladder cancer	0.000203	0.000396	CcSEcCtD
Letrozole—Feeling abnormal—Doxorubicin—urinary bladder cancer	0.000202	0.000394	CcSEcCtD
Letrozole—CYP19A1—Metabolism—SLC19A1—urinary bladder cancer	0.000201	0.00173	CbGpPWpGaD
Letrozole—Gastrointestinal pain—Doxorubicin—urinary bladder cancer	0.0002	0.000391	CcSEcCtD
Letrozole—Pruritus—Methotrexate—urinary bladder cancer	0.0002	0.00039	CcSEcCtD
Letrozole—CYP19A1—Metabolism—PRSS3—urinary bladder cancer	0.000196	0.00168	CbGpPWpGaD
Letrozole—Urticaria—Doxorubicin—urinary bladder cancer	0.000194	0.000379	CcSEcCtD
Letrozole—Abdominal pain—Doxorubicin—urinary bladder cancer	0.000193	0.000378	CcSEcCtD
Letrozole—Body temperature increased—Doxorubicin—urinary bladder cancer	0.000193	0.000378	CcSEcCtD
Letrozole—CYP3A4—Biological oxidations—HPGDS—urinary bladder cancer	0.000193	0.00166	CbGpPWpGaD
Letrozole—Diarrhoea—Methotrexate—urinary bladder cancer	0.000193	0.000377	CcSEcCtD
Letrozole—Asthenia—Epirubicin—urinary bladder cancer	0.00019	0.00037	CcSEcCtD
Letrozole—CYP2A6—Metabolism—UGT2B7—urinary bladder cancer	0.000188	0.00162	CbGpPWpGaD
Letrozole—CYP3A4—Biological oxidations—GSTT1—urinary bladder cancer	0.000188	0.00161	CbGpPWpGaD
Letrozole—Pruritus—Epirubicin—urinary bladder cancer	0.000187	0.000365	CcSEcCtD
Letrozole—Dizziness—Methotrexate—urinary bladder cancer	0.000187	0.000365	CcSEcCtD
Letrozole—CYP19A1—Integrated Breast Cancer Pathway—MYC—urinary bladder cancer	0.000186	0.00159	CbGpPWpGaD
Letrozole—CYP19A1—Integrated Breast Cancer Pathway—EGFR—urinary bladder cancer	0.000182	0.00156	CbGpPWpGaD
Letrozole—Diarrhoea—Epirubicin—urinary bladder cancer	0.000181	0.000353	CcSEcCtD
Letrozole—Vomiting—Methotrexate—urinary bladder cancer	0.00018	0.000351	CcSEcCtD
Letrozole—Rash—Methotrexate—urinary bladder cancer	0.000178	0.000348	CcSEcCtD
Letrozole—Dermatitis—Methotrexate—urinary bladder cancer	0.000178	0.000347	CcSEcCtD
Letrozole—Headache—Methotrexate—urinary bladder cancer	0.000177	0.000346	CcSEcCtD
Letrozole—Asthenia—Doxorubicin—urinary bladder cancer	0.000176	0.000343	CcSEcCtD
Letrozole—Dizziness—Epirubicin—urinary bladder cancer	0.000175	0.000341	CcSEcCtD
Letrozole—Pruritus—Doxorubicin—urinary bladder cancer	0.000173	0.000338	CcSEcCtD
Letrozole—CYP19A1—Integrated Breast Cancer Pathway—KRAS—urinary bladder cancer	0.000172	0.00147	CbGpPWpGaD
Letrozole—CYP2A6—Metabolism—CYP4B1—urinary bladder cancer	0.00017	0.00146	CbGpPWpGaD
Letrozole—Vomiting—Epirubicin—urinary bladder cancer	0.000168	0.000328	CcSEcCtD
Letrozole—Nausea—Methotrexate—urinary bladder cancer	0.000168	0.000328	CcSEcCtD
Letrozole—Diarrhoea—Doxorubicin—urinary bladder cancer	0.000167	0.000327	CcSEcCtD
Letrozole—Rash—Epirubicin—urinary bladder cancer	0.000167	0.000325	CcSEcCtD
Letrozole—Dermatitis—Epirubicin—urinary bladder cancer	0.000167	0.000325	CcSEcCtD
Letrozole—Headache—Epirubicin—urinary bladder cancer	0.000166	0.000323	CcSEcCtD
Letrozole—Dizziness—Doxorubicin—urinary bladder cancer	0.000162	0.000316	CcSEcCtD
Letrozole—CYP2A6—Metabolism—SLC19A1—urinary bladder cancer	0.00016	0.00138	CbGpPWpGaD
Letrozole—CYP19A1—Metabolism of lipids and lipoproteins—NCOR1—urinary bladder cancer	0.000157	0.00135	CbGpPWpGaD
Letrozole—Nausea—Epirubicin—urinary bladder cancer	0.000157	0.000307	CcSEcCtD
Letrozole—CYP19A1—Metabolism—TYMP—urinary bladder cancer	0.000157	0.00135	CbGpPWpGaD
Letrozole—CYP2A6—Metabolism—PRSS3—urinary bladder cancer	0.000156	0.00134	CbGpPWpGaD
Letrozole—Vomiting—Doxorubicin—urinary bladder cancer	0.000156	0.000304	CcSEcCtD
Letrozole—Rash—Doxorubicin—urinary bladder cancer	0.000154	0.000301	CcSEcCtD
Letrozole—Dermatitis—Doxorubicin—urinary bladder cancer	0.000154	0.000301	CcSEcCtD
Letrozole—Headache—Doxorubicin—urinary bladder cancer	0.000153	0.000299	CcSEcCtD
Letrozole—CYP19A1—Integrated Breast Cancer Pathway—TP53—urinary bladder cancer	0.000152	0.00131	CbGpPWpGaD
Letrozole—CYP19A1—Metabolism of lipids and lipoproteins—GPX1—urinary bladder cancer	0.000151	0.00129	CbGpPWpGaD
Letrozole—Nausea—Doxorubicin—urinary bladder cancer	0.000145	0.000284	CcSEcCtD
Letrozole—CYP19A1—Metabolism—NAT2—urinary bladder cancer	0.000142	0.00122	CbGpPWpGaD
Letrozole—CYP3A4—Biological oxidations—GSTP1—urinary bladder cancer	0.00013	0.00112	CbGpPWpGaD
Letrozole—CYP3A4—Metapathway biotransformation—GSTP1—urinary bladder cancer	0.000128	0.0011	CbGpPWpGaD
Letrozole—CYP2A6—Metabolism—TYMP—urinary bladder cancer	0.000125	0.00107	CbGpPWpGaD
Letrozole—CYP19A1—Metabolism—RRM2—urinary bladder cancer	0.000122	0.00105	CbGpPWpGaD
Letrozole—CYP3A4—Biological oxidations—GSTM1—urinary bladder cancer	0.000119	0.00103	CbGpPWpGaD
Letrozole—CYP3A4—Metapathway biotransformation—GSTM1—urinary bladder cancer	0.000118	0.00101	CbGpPWpGaD
Letrozole—CYP19A1—Metabolism—ENO2—urinary bladder cancer	0.000113	0.000973	CbGpPWpGaD
Letrozole—CYP19A1—Metabolism—HPGDS—urinary bladder cancer	0.000113	0.000973	CbGpPWpGaD
Letrozole—CYP2A6—Metabolism—NAT2—urinary bladder cancer	0.000113	0.000969	CbGpPWpGaD
Letrozole—CYP19A1—Metabolism of lipids and lipoproteins—PPARG—urinary bladder cancer	0.000113	0.000968	CbGpPWpGaD
Letrozole—CYP19A1—Metabolism—GSTT1—urinary bladder cancer	0.00011	0.000944	CbGpPWpGaD
Letrozole—CYP19A1—Metabolism of lipids and lipoproteins—CREBBP—urinary bladder cancer	0.000108	0.000929	CbGpPWpGaD
Letrozole—CYP2A6—Metabolism—RRM2—urinary bladder cancer	9.74e-05	0.000836	CbGpPWpGaD
Letrozole—CYP19A1—Metabolism—NQO1—urinary bladder cancer	9.14e-05	0.000784	CbGpPWpGaD
Letrozole—CYP2A6—Metabolism—ENO2—urinary bladder cancer	9.02e-05	0.000775	CbGpPWpGaD
Letrozole—CYP2A6—Metabolism—HPGDS—urinary bladder cancer	9.02e-05	0.000775	CbGpPWpGaD
Letrozole—CYP19A1—Metabolism of lipids and lipoproteins—PTGS2—urinary bladder cancer	8.86e-05	0.000761	CbGpPWpGaD
Letrozole—CYP2A6—Metabolism—GSTT1—urinary bladder cancer	8.75e-05	0.000751	CbGpPWpGaD
Letrozole—CYP3A4—Metabolism—GSTZ1—urinary bladder cancer	7.97e-05	0.000684	CbGpPWpGaD
Letrozole—CYP19A1—Metabolism of lipids and lipoproteins—PTEN—urinary bladder cancer	7.73e-05	0.000664	CbGpPWpGaD
Letrozole—CYP19A1—Metabolism—GSTP1—urinary bladder cancer	7.62e-05	0.000654	CbGpPWpGaD
Letrozole—CYP3A4—Metabolism—GSTO2—urinary bladder cancer	7.55e-05	0.000648	CbGpPWpGaD
Letrozole—CYP3A4—Metabolism—NAT1—urinary bladder cancer	7.55e-05	0.000648	CbGpPWpGaD
Letrozole—CYP19A1—Metabolism of lipids and lipoproteins—EP300—urinary bladder cancer	7.37e-05	0.000633	CbGpPWpGaD
Letrozole—CYP2A6—Metabolism—NQO1—urinary bladder cancer	7.27e-05	0.000624	CbGpPWpGaD
Letrozole—CYP19A1—Metabolism—TYMS—urinary bladder cancer	7.08e-05	0.000608	CbGpPWpGaD
Letrozole—CYP19A1—Metabolism—GSTM1—urinary bladder cancer	7e-05	0.000601	CbGpPWpGaD
Letrozole—CYP19A1—Metabolism—NCOR1—urinary bladder cancer	7e-05	0.000601	CbGpPWpGaD
Letrozole—CYP3A4—Metabolism—UGT2B7—urinary bladder cancer	6.91e-05	0.000593	CbGpPWpGaD
Letrozole—CYP19A1—Metabolism—GPX1—urinary bladder cancer	6.71e-05	0.000576	CbGpPWpGaD
Letrozole—CYP19A1—Metabolism—ERCC2—urinary bladder cancer	6.58e-05	0.000565	CbGpPWpGaD
Letrozole—CYP3A4—Metabolism—CYP4B1—urinary bladder cancer	6.22e-05	0.000534	CbGpPWpGaD
Letrozole—CYP19A1—Metabolism—MTHFR—urinary bladder cancer	6.19e-05	0.000531	CbGpPWpGaD
Letrozole—CYP2A6—Metabolism—GSTP1—urinary bladder cancer	6.06e-05	0.000521	CbGpPWpGaD
Letrozole—CYP3A4—Metabolism—SLC19A1—urinary bladder cancer	5.87e-05	0.000504	CbGpPWpGaD
Letrozole—CYP3A4—Metabolism—PRSS3—urinary bladder cancer	5.72e-05	0.000491	CbGpPWpGaD
Letrozole—CYP2A6—Metabolism—TYMS—urinary bladder cancer	5.64e-05	0.000484	CbGpPWpGaD
Letrozole—CYP2A6—Metabolism—GSTM1—urinary bladder cancer	5.57e-05	0.000479	CbGpPWpGaD
Letrozole—CYP2A6—Metabolism—NCOR1—urinary bladder cancer	5.57e-05	0.000479	CbGpPWpGaD
Letrozole—CYP2A6—Metabolism—GPX1—urinary bladder cancer	5.34e-05	0.000458	CbGpPWpGaD
Letrozole—CYP2A6—Metabolism—ERCC2—urinary bladder cancer	5.24e-05	0.00045	CbGpPWpGaD
Letrozole—CYP19A1—Metabolism—PPARG—urinary bladder cancer	5.02e-05	0.000431	CbGpPWpGaD
Letrozole—CYP2A6—Metabolism—MTHFR—urinary bladder cancer	4.93e-05	0.000423	CbGpPWpGaD
Letrozole—CYP19A1—Metabolism—CREBBP—urinary bladder cancer	4.82e-05	0.000414	CbGpPWpGaD
Letrozole—CYP3A4—Metabolism—TYMP—urinary bladder cancer	4.57e-05	0.000393	CbGpPWpGaD
Letrozole—CYP3A4—Metabolism—NAT2—urinary bladder cancer	4.14e-05	0.000355	CbGpPWpGaD
Letrozole—CYP2A6—Metabolism—PPARG—urinary bladder cancer	3.99e-05	0.000343	CbGpPWpGaD
Letrozole—CYP19A1—Metabolism—PTGS2—urinary bladder cancer	3.95e-05	0.000339	CbGpPWpGaD
Letrozole—CYP2A6—Metabolism—CREBBP—urinary bladder cancer	3.84e-05	0.000329	CbGpPWpGaD
Letrozole—CYP3A4—Metabolism—RRM2—urinary bladder cancer	3.57e-05	0.000307	CbGpPWpGaD
Letrozole—CYP19A1—Metabolism—PTEN—urinary bladder cancer	3.44e-05	0.000296	CbGpPWpGaD
Letrozole—CYP3A4—Metabolism—ENO2—urinary bladder cancer	3.31e-05	0.000284	CbGpPWpGaD
Letrozole—CYP3A4—Metabolism—HPGDS—urinary bladder cancer	3.31e-05	0.000284	CbGpPWpGaD
Letrozole—CYP19A1—Metabolism—EP300—urinary bladder cancer	3.28e-05	0.000282	CbGpPWpGaD
Letrozole—CYP3A4—Metabolism—GSTT1—urinary bladder cancer	3.21e-05	0.000275	CbGpPWpGaD
Letrozole—CYP2A6—Metabolism—PTGS2—urinary bladder cancer	3.14e-05	0.00027	CbGpPWpGaD
Letrozole—CYP2A6—Metabolism—PTEN—urinary bladder cancer	2.74e-05	0.000235	CbGpPWpGaD
Letrozole—CYP3A4—Metabolism—NQO1—urinary bladder cancer	2.67e-05	0.000229	CbGpPWpGaD
Letrozole—CYP2A6—Metabolism—EP300—urinary bladder cancer	2.61e-05	0.000224	CbGpPWpGaD
Letrozole—CYP3A4—Metabolism—GSTP1—urinary bladder cancer	2.22e-05	0.000191	CbGpPWpGaD
Letrozole—CYP3A4—Metabolism—TYMS—urinary bladder cancer	2.07e-05	0.000178	CbGpPWpGaD
Letrozole—CYP3A4—Metabolism—NCOR1—urinary bladder cancer	2.04e-05	0.000175	CbGpPWpGaD
Letrozole—CYP3A4—Metabolism—GSTM1—urinary bladder cancer	2.04e-05	0.000175	CbGpPWpGaD
Letrozole—CYP3A4—Metabolism—GPX1—urinary bladder cancer	1.96e-05	0.000168	CbGpPWpGaD
Letrozole—CYP3A4—Metabolism—ERCC2—urinary bladder cancer	1.92e-05	0.000165	CbGpPWpGaD
Letrozole—CYP3A4—Metabolism—MTHFR—urinary bladder cancer	1.81e-05	0.000155	CbGpPWpGaD
Letrozole—CYP3A4—Metabolism—PPARG—urinary bladder cancer	1.46e-05	0.000126	CbGpPWpGaD
Letrozole—CYP3A4—Metabolism—CREBBP—urinary bladder cancer	1.41e-05	0.000121	CbGpPWpGaD
Letrozole—CYP3A4—Metabolism—PTGS2—urinary bladder cancer	1.15e-05	9.89e-05	CbGpPWpGaD
Letrozole—CYP3A4—Metabolism—PTEN—urinary bladder cancer	1e-05	8.63e-05	CbGpPWpGaD
Letrozole—CYP3A4—Metabolism—EP300—urinary bladder cancer	9.58e-06	8.23e-05	CbGpPWpGaD
